GlaxoSmithKline (GSK)’s R&D Biopharmaceutical Pilot Plant in Upper Merion, PA is a R&D clinical trial material (CTM) manufacturing facility with an aggressive processing schedule that requires minimal shutdown interruptions. Utility reliability is paramount to achieve production demands and regulatory quality requirements. To meet the utility demands for increased CTM output, a capital investment project was required to replace the existing, obsolete high purity water (HPW) generation system and water-for-injection (WFI) generation system with new, reliable technology. This article describes how the new systems were designed and installed in a challenging space to ensure redundancy and improve sustainability.

Read this article from Pharmaceutical Technology’s 2017 Biologics and Sterile Drug Manufacturing eBook.

View other articles in the 2017 Biologics and Sterile Drug Manufacturing eBook.